文献速递炎症性肠病

炎症性肠病管理的短期与长期目标演变:做对并持久维持

Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last.
PubMed 文献 · Gastroenterology · 2022-01-04

过去十年炎症性肠病的治疗目标从症状控制转向内镜愈合和以患者为中心的指标。STRIDE-II共识将这些目标按时间线排列,并新增血清和粪便生物标志物正常化、生活质量恢复、残疾预防及儿童生长恢复等目标。克罗恩病透壁愈合和溃疡性结肠炎组织学愈合目前作为评估缓解深度的辅助指标。按达标治疗范式早期治疗是否影响疾病自然史尚不清楚,需前瞻性疾病修饰试验;SPIRIT共识为此类试验定义了评估长期影响的目标。

要点

  • 炎症性肠病治疗目标已从症状控制转向内镜愈合和以患者为中心的参数。
  • STRIDE-II共识按时间线排列短期和长期治疗目标,并新增生物标志物正常化、生活质量恢复、残疾预防和儿童生长恢复等目标。
  • 克罗恩病透壁愈合和溃疡性结肠炎组织学愈合目前作为评估缓解深度的辅助指标。

核心结论

  • 随着针对更深愈合的风险-获益平衡的数据不断出现,炎症性肠病的治疗目标可能继续演变。

研究设计与样本

  • 本文为综述,梳理炎症性肠病短期和长期治疗目标的演变及STRIDE-II和SPIRIT共识。

主要发现

  • 过去十年炎症性肠病的治疗目标从症状控制转向内镜愈合和以患者为中心的参数。
  • STRIDE-II共识将目标放在从开始治疗起的时间线上,并新增血清和粪便生物标志物正常化、生活质量恢复、残疾预防以及儿童生长恢复等目标。
  • 克罗恩病透壁愈合和溃疡性结肠炎组织学愈合目前作为评估缓解深度的辅助指标。
  • 按达标治疗范式早期治疗是否影响炎症性肠病自然史尚不清楚,需要前瞻性疾病修饰试验。
  • SPIRIT共识为这些试验定义了目标,以评估早期治疗对生活质量、残疾、疾病并发症、肿瘤性病变风险和死亡率的长期影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Short- and long-term treatment targets in inflammatory bowel diseases (IBDs) evolved during the last decade, shifting from symptom control to endoscopic healing and patient-centered parameters. The STRIDE-II consensus placed these targets on a timeline from initiating treatment and introduced additional targets, normalization of serum and fecal biomarkers, restoration of quality of life, prevention of disability, and, in children, restoration of growth. Transmural healing in Crohn's disease and histologic healing in ulcerative colitis currently serve as adjunct measures to gauge remission depth. However, whether early treatment according to a treat-to-target paradigm affects the natural course of IBD remains unclear, leading to the need for prospective disease-modification trials. The SPIRIT consensus defined the targets for these trials to assess the long-term impact of early treatment on quality of life, disability, disease complications, risk of neoplastic lesions, and mortality. As further data emerge about the risk-benefit balance of aiming toward deeper healing, the targets in treating IBDs may continue to shift.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Le Berre C, Ricciuto A, Peyrin-Biroulet L, et al. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology. 2022. PMID: 34995529. doi:10.1053/j.gastro.2021.09.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。